BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS I-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER
Therapeutic polypeptides, compositions thereof and methods of use thereof for activating NK cells and treating tumors are provided. The therapeutic polypeptides can include a first domain for binding NKG2D and a second domain for binding a tumor target.
1 - 69 . (canceled)
70 . A polypeptide comprising a first domain and a second domain, wherein the first domain comprises a first amino acid sequence that possesses at least 80% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 80% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, or at least 80% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3, wherein the first domain is capable of binding to human NKG2D with a binding affinity of about 0.01 nM to about 1000 nM, wherein the second domain comprises a second amino acid sequence capable of binding to a peptide on a tumor cell, wherein the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell, and wherein the peptide is selected from the group consisting of ERBB2, CD19, EPCAM, MS4A1, FOLH1, CEACAM5, PMEL, CLEC12A, KDR, EGFR, TAG-72 (tumor associated glycoprotein 72), disialoganglioside GD2, CD20, CD123, CD33, BCMA, CD38, B7H3/CD276, GPA33, SSTR2, GPC3, and CDH30.
71 . The polypeptide of claim 70 , wherein the second domain is an antibody.
72 . The polypeptide of claim 70 , wherein the tumor cell is selected from the group consisting of a breast cancer cell, a prostate cancer cell, a melanoma cell, an ovarian cancer cell, a gastric cancer cell, a glioblastoma cell, a neuroblastoma cell, a lung cancer cell a lymphoma cell, a leukemia cell, a colon cancer cell, a renal cell carcinoma, a pancreatic cancer cell, and a hepatocellular carcinoma cell.
73 . The polypeptide of claim 70 , wherein the first amino acid sequence possesses at least 90% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 90% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, and at least 90% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3.
74 . The polypeptide of claim 70 , wherein the first amino acid sequence possesses at least 80% homology to SEQ ID NOs: 1, 2 or 3.
75 . A pharmaceutical composition comprising a polypeptide and a pharmaceutically acceptable excipient, wherein the polypeptide comprises a first domain and a second domain, wherein the first domain comprises a first amino acid sequence that possesses at least 80% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 80% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, or at least 80% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3, wherein the first domain is capable of binding to human NKG2D with a binding affinity of about 0.01 nM to about 1000 nM, wherein the second domain comprises a second amino acid sequence capable of binding to a peptide on a tumor cell, wherein the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell, and wherein the peptide is selected from the group consisting of ERBB2, CD19, EPCAM, MS4A1, FOLH1, CEACAM5, PMEL, CLEC12A, KDR, EGFR, TAG-72 (tumor associated glycoprotein 72), disialoganglioside GD2, CD20, CD123, CD33, BCMA, CD38, B7H3/CD276, GPA33, SSTR2, GPC3, and CDH30.
76 . The pharmaceutical composition of claim 75 , wherein the second domain is an antibody.
77 . The pharmaceutical composition of claim 75 , wherein the tumor cell is selected from the group consisting of a breast cancer cell, a prostate cancer cell, a melanoma cell, an ovarian cancer cell, a gastric cancer cell, a glioblastoma cell, a neuroblastoma cell, a lung cancer cell, a lymphoma cell, a leukemia cell, a colon cancer cell, a renal cell carcinoma, a pancreatic cancer cell, and a hepatocellular carcinoma cell.
78 . The pharmaceutical composition of claim 75 , wherein the first amino acid sequence possesses at least 90% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 90% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, and at least 90% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3.
79 . The pharmaceutical composition of claim 75 , wherein the first amino acid sequence possesses at least 80% homology to SEQ ID NOs: 1, 2 or 3.
80 . The pharmaceutical composition of claim 75 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of a diluent, a binder, a filler, a buffering agent, a pH modifying agent, a disintegrant, a dispersant, a preservative, a lubricant, a taste-masking agent, a flavoring agent, and a coloring agent.
81 . A polypeptide comprising a first domain and a second domain, wherein the first domain comprises a first amino acid sequence that possesses at least 80% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 80% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, or at least 80% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3, wherein the first domain is capable of binding to human NKG2D with a binding affinity of about 0.01 nM to about 1000 nM, wherein the second domain comprises a second amino acid sequence capable of binding to a peptide on a tumor cell, wherein the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell, wherein the peptide is selected from the group consisting of ERBB2, CD19, EPCAM, MS4A1, FOLH1, CEACAM5, PMEL, CLEC12A, KDR, EGFR, TAG-72 (tumor associated glycoprotein 72), disialoganglioside GD2, CD20, CD123, CD33, BCMA, CD38, B7H3/CD276, GPA33, SSTR2, GPC3, and CDH30, and wherein the second domain is not a cytokine.
82 . A method for treating a tumor in a subject in need thereof comprising administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition comprising a polypeptide and a pharmaceutically acceptable excipient, wherein the polypeptide comprises a first domain and a second domain, wherein the first domain comprises a first amino acid sequence that possesses at least 80% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 80% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, or at least 80% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3, wherein the first domain is capable of binding to human NKG2D with a binding affinity of about 0.01 nM to about 1000 nM, wherein the second domain comprises a second amino acid sequence capable of binding to a peptide on a tumor cell, wherein the peptide is either specific to the tumor cell or overexpressed on the tumor cell compared to a non-tumor cell of the same tissue origin as the tumor cell, and wherein the peptide is selected from the group consisting of ERBB2, CD19, EPCAM, MS4A1, FOLH1, CEACAM5, PMEL, CLEC12A, KDR, EGFR, TAG-72 (tumor associated glycoprotein 72), disialoganglioside GD2, CD20, CD123, CD33, BCMA, CD38, B7H3/CD276, GPA33, SSTR2, GPC3, and CDH30.
83 . The method of claim 82 , wherein the second domain is an antibody.
84 . The method of claim 82 , wherein the tumor cell is selected from the group consisting of a breast cancer cell, a prostate cancer cell, a melanoma cell, an ovarian cancer cell, a gastric cancer cell, a glioblastoma cell, a neuroblastoma cell, a lung cancer cell, a lymphoma cell, a leukemia cell, a colon cancer cell, a renal cell carcinoma, a pancreatic cancer cell, and a hepatocellular carcinoma cell.
85 . The method of claim 82 , wherein the first amino acid sequence possesses at least 90% homology to amino acid positions 48 to 67 and 110 to 147 of SEQ ID NO: 1, at least 90% homology to amino acid positions 49 to 68 and 111 to 148 of SEQ ID NO: 2, and at least 90% homology to amino acid positions 48 to 66 and 111 to 148 of SEQ ID NO: 3.
86 . The method of claim 82 , wherein the first amino acid sequence possesses at least homology to SEQ ID NOs: 1, 2 or 3.
87 . The method of claim 82 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of a diluent, a binder, a filler, a buffering agent, a pH modifying agent, a disintegrant, a dispersant, a preservative, a lubricant, a taste-masking agent, a flavoring agent, and a coloring agent.
88 . The method of claim 82 , wherein the step of administering is performed orally or otherwise peripherally.
89 . The method of claim 82 , wherein the step of administering is peripherally and is selected from the group consisting of intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository.
90 . The method of claim 82 , wherein the step of administering is performed by subcutaneous, intramuscular, or intravenous injection.